Trade FibroGen, Inc - FGEN CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023512% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.00129% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 0.75 |
| Open | 0.67 |
| 1-Year Change | -61.93% |
| Day's Range | 0.65 - 0.75 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Feb 21, 2025 | 0.68 | 0.00 | 0.00% | 0.68 | 0.76 | 0.63 |
| Feb 20, 2025 | 0.75 | -0.03 | -3.85% | 0.78 | 0.85 | 0.64 |
| Feb 19, 2025 | 0.54 | -0.01 | -1.82% | 0.55 | 0.56 | 0.51 |
| Feb 18, 2025 | 0.56 | 0.02 | 3.70% | 0.54 | 0.60 | 0.53 |
| Feb 14, 2025 | 0.52 | 0.02 | 4.00% | 0.50 | 0.57 | 0.49 |
| Feb 13, 2025 | 0.50 | 0.06 | 13.64% | 0.44 | 0.50 | 0.43 |
| Feb 12, 2025 | 0.44 | -0.01 | -2.22% | 0.45 | 0.45 | 0.43 |
| Feb 11, 2025 | 0.45 | -0.03 | -6.25% | 0.48 | 0.49 | 0.45 |
| Feb 10, 2025 | 0.48 | 0.00 | 0.00% | 0.48 | 0.49 | 0.46 |
| Feb 7, 2025 | 0.48 | 0.00 | 0.00% | 0.48 | 0.49 | 0.46 |
| Feb 6, 2025 | 0.48 | 0.02 | 4.35% | 0.46 | 0.49 | 0.46 |
| Feb 5, 2025 | 0.48 | 0.05 | 11.63% | 0.43 | 0.48 | 0.43 |
| Feb 4, 2025 | 0.44 | -0.01 | -2.22% | 0.45 | 0.46 | 0.43 |
| Feb 3, 2025 | 0.45 | 0.01 | 2.27% | 0.44 | 0.46 | 0.43 |
| Jan 31, 2025 | 0.46 | -0.02 | -4.17% | 0.48 | 0.48 | 0.45 |
| Jan 30, 2025 | 0.47 | 0.01 | 2.17% | 0.46 | 0.48 | 0.44 |
| Jan 29, 2025 | 0.45 | -0.02 | -4.26% | 0.47 | 0.47 | 0.44 |
| Jan 28, 2025 | 0.46 | 0.00 | 0.00% | 0.46 | 0.47 | 0.46 |
| Jan 27, 2025 | 0.46 | -0.02 | -4.17% | 0.48 | 0.51 | 0.46 |
| Jan 24, 2025 | 0.48 | -0.01 | -2.04% | 0.49 | 0.51 | 0.48 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
FibroGen, Inc Company profile
About FibroGen Inc
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing a pipeline of first-in-class therapeutics. The Company applies its capabilities in hypoxia-inducible factor (HIF) biology, 2-oxoglutarate enzymology, and connective tissue growth factor (CTGF) biology to advance medicines for the treatment of anemia, fibrotic disease, and cancer. The Company’s product Roxadustat is an oral small molecule inhibitor of HIF-prolyl hydroxylase (HIF-PH) activity for the treatment of anemia caused by chronic kidney disease (CKD). It is also developing Roxadustat for anemia associated with myelodysplastic syndromes (MDS). The Company is also developing Roxadustat for the treatment of chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD).
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, FibroGen Inc revenues increased 33% to $235.3M. Net loss increased 53% to $290M. Revenues reflect Europe segment increase of 95% to $131.2M. Higher net loss reflects Research and Development -Balancing increase of 68% to $346.5M (expense), General and Administrative -Balancing increase of 27% to $89.9M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$2.11 to -$3.14.
| Industry: | Biotechnology & Medical Research (NEC) |
409 Illinois Street
SAN FRANCISCO
CALIFORNIA 94158
US
News
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025
Ripple XRP price prediction: Third-party price target
Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com
15:29, 6 February 2025
Apple (AAPL) stock price forecast: third-party price target
We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.
11:22, 6 February 2025
FARTCOIN price prediction: Third-party price target
Read our FARTCOIN price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:18, 29 January 2025
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com